Experimental research on the role of the putative virulence factor sprE of Enterococcus faecalis in mouse and rabbit models

Chinese Journal of Microbiology and Immunology

Volumn 27, Issue 2, 2007, Pages 155-159

  Wu, Li Xian ^a   Huang, Wen Xiang ^a   Sun, Xiao Ping ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Endocarditis models; Enterococcus faecalis; Peritonitis models; sprE gene; Virulence

Indexed keywords

RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SPRE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL VIRULENCE; CONTROLLED STUDY; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; EXPERIMENTAL STUDY; LD 50; MEDICAL RESEARCH; MOUSE; NONHUMAN; PERITONITIS; PROTEIN FOLDING; RABBIT; SURVIVAL;

EID: 34249301723     PISSN: 02545101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Jones RN. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med, 1996, 100(6A): 3-12.
2. Kristich CJ, Li YH, Cvitkovitch DG, et al. Esp-independent biofilm formation by Enterococcus faecalis. J Bacteriology, 2004, 186(1): 154-163.
3. Mylonakis E, Engelbert M, Qin X, et al. The Enterococcus faecalis fsrB gene, a key component of the fsr quorum-sensing system, is associated with virulence in the rabbit endophthalmitis model. Infect Immun, 2002, 70(8): 4678-4681.
4. Ibrahim YM, Alison R K, McCluskey J, et al. Role of HtrA in the Virulence and Competence of Streptococcus pneumoniae . Infect Immun, 2004, 72(6): 3584-3591.
5. Chinese source
6. Jacqueline C, Asseray N, Batard E, et al. In vivo efficacy of linezolid in combination with gentamicin for the treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents, 2004, 24(4): 393-396.
7. Dubé L, Caillon J, Gras-Le Guen C, et al. Simulation of human gentamicin pharmacokinetics in an experimental Enterococcus faecalis endocarditis model. Antimicrob Agents Chemother, 2003, 47(11): 3663-3666.
8. Singh KV, Qin X, Weinstock GM, et al. Generation and testing of mutants of Enterococcus faecalis in a mouse peritonitis model. J Infect Dis, 1998, 178(5): 1416-1420.
9. XU Y, Kavindra V, Qin X, et al. Analysis of a gene cluster of Enterococcus faecalis involved in polysaccharide biosynthesis. Infect Immun, 2000, 68(2): 815-823.
10. Reed LJ, Muench H. A simple method of estimating fifty, percent endpoints. Am J Hyg, 1938, 27: 493-497.
11. Dupont H, Montravers P, Mohler J, et al. Disparate findings on the role of virulence factors of Enterococcus faecalis in mouse and rat models of peritonitis. Infect Immun, 1998, 66(6): 2570-2575.
12. Chinese source
13. Kawalec M, Gniadkowski M, Zaleska M, et al. Outbreak of vancomycin-resistant Enterococcus faecium of the phenotype VanB in a hospital in Warsaw, Poland: probable transmission of the resistance determinant into an endemic vancomycin-susceptible strain. J Clin Microbiol, 2001, 39(5): 1781-1787.
14. Coque TM, Willems R, Canton R, et al. High occurrence of esp among ampicillin-resistant and vancomycin-susceptible Enterococcus faecium clones from hospitalized patients. J Antimicrob Chemother, 2002, 50(6): 1035-1038.
15. Dalla Costa LM, Reynolds PE, Souza HA, et al. Characterization of a divergent VanD-type resistance element from the first glycopeptide-resistant strain of Enterococcus faecium isolated in Brazil. Antimicrob Agents Chemother, 2000, 44(12): 3444-3446.